Physician profile
Bob I Wodecki
NPI 1649270190
$35,393.09
in general payments reported to CMS, 2019-2025
66 companies · $7,138 in 2025
The $7,138 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,977 · 2020: $3,050 · 2021: $4,208 · 2022: $5,520 · 2023: $5,126 · 2024: $5,373 · 2025: $7,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $2,280 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,020.49 |
| Consulting Fee | $2,280.00 |
| Education | $336.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,245.98 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $4,897.30 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $4,300.29 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $1,933.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,815.26 | 2019-2025 | |
| Ucb, INC. | $1,498.07 | 2019-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $1,486.50 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $1,155.55 | 2021-2025 | Saphnelo, Airsupra |
| Horizon Therapeutics Plc | $1,130.15 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $1,074.97 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $924.04 | 2019-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $923.49 | 2020-2025 | Acthar |
| Radius Health, INC. | $850.64 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $806.06 | 2019-2025 | Ofev, Cyltezo |
| Genentech USA, INC. | $694.00 | 2019-2025 | Actemra, Gazyva, Rituxan |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Wodecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.